A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer’s disease William James Deardorff, George T Grossberg Department of Psychiatry ... Grossberg 0 0 Department of Psychiatry, St Louis University School of Medicine , St Louis, MO , USA Currently available therapies for the treatment of Alzheimer's disease (AD) consist of cholinesterase
Grossberg 1 James E Galvin 7 Jeffrey L Cummings 5 6 Tillmann Krahnke 4 Christine Strohmaier 4 0 Alzheimer's Disease and Other Cognitive Disorders Unit, ICN, Hospital Clínic i Universitari, IDIBAPS
Received 10 May 2011; Accepted 1 July 2011 Academic Editor: Bjorn A. Meyerson Copyright © 2011 Bishnu Subedi and George T. Grossberg. This is an open access article distributed under the Creative Commons
Critical appraisal and role of memantine extended-release in the management of Alzheimer’s disease Indrapal Singh, George T GrossbergDepartment of Neurology and Psychiatry, St Louis University School of Medicine, St Louis, MO, USAAbstract: Alzheimer’s disease (AD) is a progressive, degenerative brain disease. Currently available US FDA-approved pharmacological management options...
Medicine, St. Louis, MO 63104, USA Received 21 April 2010; Accepted 27 July 2010 Academic Editor: Ricardo Nitrini Copyright © 2010 Dawit A. Weldemichael and George T. Grossberg. This is an open access
Introduction Immediate-release memantine (10 mg, twice daily) is approved in the USA for moderate-to-severe Alzheimer’s disease (AD). This study evaluated the efficacy, safety, and tolerability of a higher-dose, once-daily, extended-release formulation in patients with moderate-to-severe AD concurrently taking cholinesterase inhibitors. Methods In this 24-week, double-blind...
. Industry, academic, and regulatory agency viewpoints were discussed, followed by robust audience participation. The session topic was introduced by George T. Grossberg (St. Louis University School of